Sign in

    Timothy Stabosz

    Research Analyst at Private Investor

    Timothy Stabosz is a Financial Blogger and Private Investor specializing in general U.S. equities, with notable coverage including Claude Resources and other public companies. He has maintained a 50% success rate on TipRanks, ranking #8,187 out of over 30,000 financial bloggers, with an average return of 14.2% per rating based on a 1-year holding period since 2015. Stabosz has been actively publishing investment research on Seeking Alpha and other platforms since at least 2010, drawing on multiple decades of market experience as a private investor and former public official. While formal broker-dealer registrations or securities licenses are not specified, Stabosz is recognized for his strong analytical insights and consistent track record of profitable investment calls in the U.S. market.

    Timothy Stabosz's questions to Adicet Bio (ACET) leadership

    Timothy Stabosz's questions to Adicet Bio (ACET) leadership • Q1 2019

    Question

    Timothy Stabosz, a private investor, sought reassurance regarding bank support for the ongoing strategic alternatives process, the status of the company's dividend, the future trend of failure-to-supply penalties, and whether the seven-month duration of the strategic review should be seen as a negative indicator.

    Answer

    CFO Becky Roof affirmed that the successful negotiation of a recent waiver is a strong indication of the banks' support for the company. President and CEO Bill Kennally stated that the board will decide on the dividend in December but expects consistency with historical payments. He also confirmed that failure-to-supply penalties are expected to continue trending lower and become non-material. Regarding the strategic review, he advised against interpreting the timeline as either a positive or negative sign.

    Ask Fintool Equity Research AI

    Timothy Stabosz's questions to Adicet Bio (ACET) leadership • Q4 2018

    Question

    Timothy Stabosz asked for commentary on the stability and future performance of the Performance Chemicals and Pharmaceutical Intermediates divisions, given their importance to the company's value. He also pressed for details on the 'breakup ability' of the businesses. In a follow-up, he questioned the rationale for maintaining a $0.01 dividend and asked if any undisclosed material news could explain the recent stock price decline beyond the S&P 600 delisting.

    Answer

    President and CEO William Kennally expressed high confidence in the stable cash contributions from the chemicals and ingredients businesses, citing strong sourcing and strategic focus. While declining to comment on specifics of a potential breakup, he confirmed the company is 'well in control' of the analysis. Regarding the dividend, Kennally and Interim CFO Rebecca Roof noted it reflects a commitment to shareholders and that bank approval signals confidence. Roof also confirmed there was no undisclosed material information causing the stock's decline.

    Ask Fintool Equity Research AI